1 year ago
Latest news on Janssen CAR-T Multiple Myeloma product Ciltacabtagene Autoleucel(Carvykti,LCAR-B38M,JNJ-4528) Ciltacabtagene Autoleucel (LCAR-B38M, JNJ-4528, Cilta-cel, Carvykti) Status: Approved fo...
1 year ago
CART T Multiple Myeloma Benefits Relapsed or Refractory Adult Patients CARsgen Therapeutics recently announced that the National Medical Products Administration (NMPA) of China has officially appro...
1 year ago
The Beacon of BCMA CAR-T Myeloma Therapy Multiple Myeloma Awareness Month is a global social awareness initiative held annually in March to raise awareness about multiple myeloma (plasma cell malig...
1 year ago
The Revolutionary Transformation of BCMA CAR-T Multiple Myeloma Multiple myeloma (MM) is the second most common hematological malignancy in both China and the United States. Over the past decade, t...
1 year ago
Current Status and Future Trends of CAR-T For Myeloma On March 2-3, 2024, the 7th Beijing Thrombosis and Hemostasis Conference and the 5th Beijing Hematologic Malignancies and Immunology Summit, ho...
1 year ago
⛵️GUIDE TO PAYMENT SERVICES IN CHINA⛵️ 🚢Welcome to China! Now, you have a number of payment options at your fingertips while in China, ranging from mobile payments to bank cards and cash. 🚁The digi...
1 year ago
CAR-T Therapy For Multiple Myeloma: A Challenging Yet Promising Path In the not-too-distant future, CAR-T cell therapy products for multiple myeloma will gradually be launched and quickly enter the...
1 year ago
🍀Чудесное путешествие через границы: триумф мистера Баранкова с китайской терапией CAR-T🍀 ЧудесноеПутешествие 🌿Познакомьтесь с мистером Баранковым, 68-летним пациентом из Санкт-Петербурга, Россия, ...
1 year ago
Carvykti Indication for Relapsed or Refractory Multiple Myeloma in Adult Patients Carvykti Indication Carvykti (ciltacabtagene autoleucel, cilta-cel) is a B-cell maturation antigen (BCMA)-directed ...
1 year ago
🍀Miraculous Journey Across Borders: Mr. Barankov’s Triumph with CAR-T Therapy in China 🍀 Hope of patients 🌱Meet Mr. Barankov a 68-year-old patient from Saint Petersburg, Russia, who was u...
1 year ago
Ciltacabtagene Autoleucel FDA Approval For The Treatment Of Relapsed/Refractory Multiple Myeloma Cittacatagene Autoleucel approved for launch in the United States On February 28, 2022, the U.S. FDA...
1 year ago
Shanghai Hospital Achieves Complete Remission and Discharge of the 100th Patient with Relapsed/Refractory Lymphoma Treated with CAR-T Therapy Lymphoma Ruijin Hospital, affiliated with Shanghai Jiao...
By using our site, you agree to our Terms and Conditions and Privacy Policy.Advanced Medicine In China does not provide medical advice, diagnosis, or treatment. The information provided on this site is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her existing physician.
© Copyright 2023 Advanced Medicine In China. All rights reserved.
